Moyamoya disease is an idiopathic vascular disorder of the intracranial arteries.
Introduction

Moyamoya disease (Mendelian Inheritance in Man
[MIM] number 607151) is a rare idiopathic progressive disorder characterized by occlusive lesions in the supraclinoid internal carotid artery and its main branches in the circle of Willis. The reduction in blood flow in the regions affected by the occlusive lesions is compensated by the development of a fine vascular network that resembles``puffs of smoke'' (``moyamoya'' in Japanese). 12, 13) Moyamoya disease occurs with the highest prevalences in East Asian countries such as Japan, Korea, and China, especially compared with other countries worldwide. 2, 7, 10) We previously identified a susceptibility locus for familial moyamoya disease on 17q25.3. 11) Significant associations with genes in this region had been reported, 4, 8) but rigorous identification had not been determined. The ring finger 213 (RNF213) gene was finally identified as a susceptibility gene for moyamoya disease by the conventional rigorous positional cloning approach, exome analysis, and functional analysis using zebrafish. 9) Overall, 74.5% of East Asian patients with moyamoya disease carry the rare founder variant p.R4810K of RNF213. However, a gradient of prevalence was observed in patients with moyamoya disease: 90% in Japanese, 79% in Korean, and 23% in Chinese patient populations. On the other hand, no gradient of prevalence was observed in these three general populations. In total, 2.4% of the East Asian general population carries p.R4810K. The minor allele frequencies of p.R4810K were 1.4%, 1.3%, and 1.0% for the Japanese, Korean, and Chinese in general populations, respectively. 9) These similar allele frequencies of p.R4810K in these three East Asian general populations do not explain the lower frequency of Chinese patients with moyamoya disease compared with Japanese and Korean patients with moyamoya disease. Moyamoya disease occurs in approximately one of 300 carriers in Japan. 8) This discrepancy in the allele frequency between cases and controls in Chinese people might be attributable to selection bias in the general populations in the previous study. 9) The primary aim of the present study was to estimate the population susceptible to moyamoya disease by conducting large scale screening for p.R4810K in general populations in East and Southeast Asia. The secondary aim was to estimate association of the p.R4810K variant of RNF213 in patients with moyamoya disease.
Materials and Methods
A total of 2,508 unrelated participants from East Asian and Southeast Asian countries were recruited, comprising 587 Chinese, 294 Korean, 1474 Japanese, 103 Vietnamese, and 50 Filipino people ( Table 1 ). The Japanese participants were recruited from mainland Japan, including Hokkaido, Honshu, Shikoku, and Kyushu, and Okinawa. The Korean participants were recruited from five locations. The Chinese participants were recruited from 11 locations. Blood samples were obtained from two sources. One source was the Kyoto University Human Specimen Bank, which collected blood samples from the 1990s and 2000s as previously described. 5 Peripheral blood (10 ml) was collected from all participants. Genomic deoxyribonucleic acid (DNA) was extracted from the blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, Maryland, USA) according to the manufacturer's protocol. The quality and concentration of the extracted DNA were assessed using an Infinite } M200 PRO (TECAN, Kawasaki, Kanagawa). The DNA was stored in a freezer at -209 C until analysis.
Genotyping of p.R4810K in all participants was conducted using a TaqMan } probe (Custom TaqMan } SNP Genotyping Assays; Applied Biosystems, Foster City, CA, USA) and a 7300/7500 Real-Time PCR System (Applied Biosystems) according to the manufacturer's protocols. Briefly, the polymerase chain reaction (PCR) amplifications were performed with 1-20 ng of purified genomic DNA, 0.1 ml of 40× SNP Genotyping Assay, 6.25 ml of 2× TaqMan } Universal PCR Master Mix, No AmpErase } UNG, and 5.15 ml of deoxyribonucleasefree water. The final reaction volume was 12.5 ml/well in 96-well plates. The standard protocol for the cycling conditions was maintenance for 10 minutes at 959 C for AmpliTaq Gold } (Applied Biosystems) enzyme activation, followed by 40 cycles of 15 seconds at 929 C for denaturation, and 1 minute at 609 C for annealing/extension. After each PCR amplification, an endpoint plate read was performed using the Real-Time PCR System (Applied Biosystems). The associated sequence detection system software uses the fluorescence measurements taken during the plate read to plot fluorescence (normalized reporter signal: Rn) values based on the signals from each well. The plotted fluorescence signals indicate which alleles are present in each sample.
Results
The demographic features of all participants in this study are shown in Table 1 . The sampled cities covered 234.02 million people. A total of 2,508 participants from three East Asian countries and two Southeast Asian countries were recruited from 1987 The geographic distributions of p.R4810K in the different ethnicities are shown in Table 2 and Fig. 1 . p.R4810K was detected in East Asian populations, but not in Southeast Asian populations. p.R4810K was detected at allele frequencies of 0.43%, 1.36%, and 1.36% in the Chinese, Korean, and Japanese populations, respectively. p.R4810K was detected at an allele frequency of about 1.00% in 4 of 11 investigated locations in China, suggesting that the distribution of p.R4810K was heterogeneous and limited to certain specific locations in China. In contrast, p.R4810K was homogeneously located throughout Korea and Japan at relatively high allele frequencies of 1.00-1.72%. p.R4810K was not detected in 49 Taiwanese, 103 Vietnamese, and 50 Filipino participants.
Discussion
The present study confirmed the presence of similar allele frequencies of the variant p.R4810K of RNF213 in the Japanese and Korean general populations. However, expansion of the examined population revealed that the allele frequency of p.R4810K in the Chinese population was 0.43%, only one-third of the frequency in the Japanese or Korean populations. Therefore, our previous observation was considered to be attributable to selection bias. 9) The lower prevalence of p.R4810K in the Chinese general population might be proportional to the lower carrier rate (i.e., 23%) in Chinese patients. In accordance with this observation, a single dominant polymorphism may be associated with Japanese or Korean patients, whereas various polymorphisms in RNF213 may be associated with Chinese patients. In fact, we observed five additional mutations in Chinese patients but no additional mutations in Korean or Japanese patients. 9) In the present study, magnetic resonance angiography was only conducted for limited numbers of participants. This limitation did not affect our results because of the very low prevalences of moyamoya disease in the general populations. The estimated total numbers of carriers were 11.41 million for the Chinese, 1.36 million for the Korean, and 3.39 million for the Japanese populations. Assuming that moyamoya disease occurs in one of 300 carriers with p.R4810K, 8, 9) the estimated numbers of patients with moyamoya disease attributable to p.R4810K are 38,000 in the Chinese, 4,500 in the Korean, and 11,300 in the Japanese populations. Although these numbers are very approximate and minimum estimates, because only the p.R4810K variant is considered, the large number of potential sufferers suggests that more attention should be paid to moyamoya disease in East Asian countries.
Differences in the clinical profiles of moyamoya disease have been recognized in China, Korea, and Japan. 1, 3) However, the differences between the clinical profiles of Korean and Japanese patients are unlikely to be explained by genetic differences. Specific factor(s) other than the genetic factor are needed to explain the variations in the clinical phenotypes and low penetrance among carriers. 8, 9) Therefore, unknown modifier factor(s) may also be contributory to the differences in the clinical phenotypes. Further research is needed to identify such factor(s), which may also be crucial for the development of moyamoya disease among carriers of variant p.R4810K in RNF213.
